ResMed Inc.

Day range

$248.72 – $255.57

Open

$251.83

Prev close

$252.86

Volume

1.03M

Market cap

$35.59B

Shares out

140.64M

P/E

23.36

P/S

6.30

P/B

5.40

P/FCF

21.58

ROE

23.1%

ROA

17.0%

Debt/Equity

0.10

Div yield

0.98%

As of Oct 22, 2026

• Shareholder returnsSep 1, 2026

  On August 31, 2026, ResMed Inc. (the "Company") entered into an accelerated share repurchase agreement (the "ASR Agreement") with Citibank, N.A. ("Citibank") to repurchase $450.0 million of the Company's shares of common stock... The Company is conducting the accelerated share repurchase under a repurchase authorization for an aggregate of 20,000,000 shares of Common Stock approved by its board of directors in February 2014.

• Auditor mattersAug 17, 2026

  On August 13, 2026, KPMG was dismissed, effective as of that date. The reports of KPMG on the Company's consolidated financial statements for the fiscal years ended June 30, 2026 and 2025 did not contain any adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope, or accounting principles.

• Shareholder returnsAug 6, 2026

  On August 6, 2026, we announced that our board of directors declared a quarterly cash dividend of US $0.66 per share, representing an increase of 10% over the previous quarterly dividend. The dividend will have a record date of August 20, 2026, payable on September 24, 2026.

• Guidance and outlookJul 7, 2026

  Resmed reiterates its full year fiscal year 2026 outlook for non-GAAP gross margin, non-GAAP SG&A as a percentage of revenue, R&D as a percentage of revenue, and non-GAAP tax rate, as provided on Resmed's third quarter fiscal year 2026 earnings call on April 30, 2026.

• Executive leadershipApr 30, 2026

  Mr. Bloomer's compensation will include annual base salary of $725,000, a sign-on bonus of $150,000, an annual short-term cash incentive bonus target of 80% of his base salary, which will be, payable pro-rata for fiscal year 2026. Mr. Bloomer will receive a long-term performance equity grant of $3,300,000 when he joins the Company.

• MEDPMedpace Holdings, Inc. Common Stock+0.00%
• HIMSHims & Hers Health, Inc.+0.00%
• EHCEncompass Health Corporation Common Stock+0.00%

Days to cover

9.9

Short interest

12.78M

Avg volume

1.29M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Will ResMed (RMD) Beat Estimates Again in Its Next Earnings Report?
  positiveZacks Investment Research· Oct 23, 2026
• ResMed Set to Report Q1 Earnings: What's in the Cards for the Stock?
  neutralZacks Investment Research· Oct 23, 2026
• ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
  neutralZacks Investment Research· Oct 22, 2026
• Global Digital Health and Remote Patient Monitoring Strategic Market Report, 2026-2031 | 20.2% CAGR to $80.8 Billion as Connected Care and Wearables Scale
  positiveGlobeNewswire Inc.· Oct 21, 2026
• Is This the Right Time to Retain Resmed Stock in Your Portfolio?
  neutralZacks Investment Research· Sep 15, 2026